Response Genetics, Inc (RGDXQ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2015 | -13.08 Million USD | -275.75% |
| 2014 | 7.44 Million USD | 208.62% |
| 2013 | -6.85 Million USD | 12.1% |
| 2012 | -7.79 Million USD | -2414.85% |
| 2011 | -310.11 Thousand USD | 92.47% |
| 2010 | -4.12 Million USD | 41.63% |
| 2009 | -7.05 Million USD | 26.05% |
| 2008 | -9.54 Million USD | 43.93% |
| 2007 | -17.02 Million USD | -304.06% |
| 2006 | -4.21 Million USD | -119.81% |
| 2005 | -1.91 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2015 FY | -13.08 Million USD | -275.75% |
| 2015 Q1 | 9.2 Million USD | 23.67% |
| 2014 FY | 7.44 Million USD | 208.62% |
| 2014 Q1 | -3.71 Million USD | 45.87% |
| 2014 Q2 | -440.55 Thousand USD | 88.13% |
| 2014 Q3 | 3.69 Million USD | 939.34% |
| 2014 Q4 | 7.44 Million USD | 101.36% |
| 2013 Q1 | -6.83 Million USD | 12.41% |
| 2013 Q4 | -6.85 Million USD | -111.5% |
| 2013 FY | -6.85 Million USD | 12.1% |
| 2013 Q2 | -4.48 Million USD | 34.28% |
| 2013 Q3 | -3.24 Million USD | 27.8% |
| 2012 Q4 | -7.79 Million USD | 18.41% |
| 2012 Q2 | -1.24 Million USD | 71.17% |
| 2012 Q1 | -4.31 Million USD | -1291.73% |
| 2012 FY | -7.79 Million USD | -2414.85% |
| 2012 Q3 | -9.55 Million USD | -668.31% |
| 2011 FY | -310.11 Thousand USD | 92.47% |
| 2011 Q4 | -310.11 Thousand USD | 85.92% |
| 2011 Q3 | -2.2 Million USD | 33.68% |
| 2011 Q2 | -3.32 Million USD | -72.62% |
| 2011 Q1 | -1.92 Million USD | 53.29% |
| 2010 FY | -4.12 Million USD | 41.63% |
| 2010 Q1 | -9.09 Million USD | -28.8% |
| 2010 Q2 | -6.58 Million USD | 27.51% |
| 2010 Q4 | -4.12 Million USD | 24.25% |
| 2010 Q3 | -5.43 Million USD | 17.46% |
| 2009 Q4 | -7.05 Million USD | 24.1% |
| 2009 FY | -7.05 Million USD | 26.05% |
| 2009 Q3 | -9.29 Million USD | -32.06% |
| 2009 Q2 | -7.04 Million USD | 30.73% |
| 2009 Q1 | -10.16 Million USD | -6.5% |
| 2008 Q1 | -17.53 Million USD | -3.0% |
| 2008 Q3 | -12.27 Million USD | 18.87% |
| 2008 Q4 | -9.54 Million USD | 22.24% |
| 2008 Q2 | -15.12 Million USD | 13.72% |
| 2008 FY | -9.54 Million USD | 43.93% |
| 2007 Q4 | -17.02 Million USD | 4.73% |
| 2007 Q2 | -19.42 Million USD | -649.07% |
| 2007 Q1 | -2.59 Million USD | 38.44% |
| 2007 FY | -17.02 Million USD | -304.06% |
| 2007 Q3 | -17.86 Million USD | 8.02% |
| 2006 FY | -4.21 Million USD | -119.81% |
| 2006 Q4 | -4.21 Million USD | -81.42% |
| 2006 Q3 | -2.32 Million USD | 0.0% |
| 2005 FY | -1.91 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 693.2% |
| Arrayit Corporation | 1.05 Million USD | 1339.698% |
| Atlantic International Corp. | 236.49 Thousand USD | 5633.286% |
| Biocept, Inc. | -788 Thousand USD | -1560.66% |
| Bioqual, Inc. | -12 Million USD | -8.985% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 57648.705% |
| DermTech, Inc. | 17.65 Million USD | 174.129% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 97.714% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | -77.391% |
| iMD Companies, Inc. | 1.11 Million USD | 1272.671% |
| IDenta Corp. | 524.85 Thousand USD | 2593.274% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 270.081% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -48452.983% |
| InVitro International | -313.14 Thousand USD | -4078.935% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 935.678% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -1835243.619% |
| Medical Imaging Corp. | 3.79 Million USD | 445.192% |
| NovelStem International Corp. | 3.52 Million USD | 471.599% |
| Optigenex Inc. | 8.93 Million USD | 246.475% |
| PharmChem, Inc. | -1.49 Million USD | -775.662% |
| Proteome Sciences plc | 14.57 Million USD | 189.794% |
| Rennova Health, Inc. | 14.82 Million USD | 188.241% |
| RushNet, Inc. | 4.8 Million USD | 372.577% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 9751.225% |
| Stella Diagnostics Inc. | 6.19 Million USD | 311.301% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 833.356% |
| Todos Medical Ltd. | 38.31 Million USD | 134.155% |